This clinical trial is focused on patients with atrial fibrillation, a condition where the heart beats irregularly, and those experiencing acute coronary syndrome or chronic coronary syndrome, which are types of heart problems. The study is investigating the use of a medication called Lixiana, which contains the active substance edoxaban. This medication is available in two forms: 30 mg and 60 mg film-coated tablets. The purpose of the study is to find the best way to prevent blood clots in these patients, especially after they have undergone a procedure called percutaneous coronary intervention (PCI), which is used to open blocked heart arteries.
Participants in the study will be given either the standard treatment or a new treatment strategy involving Lixiana. The study will compare the safety and effectiveness of these treatments by looking at the risk of bleeding and the occurrence of heart-related events like heart attacks or strokes. The study will last for several weeks, with follow-ups to check on the participants’ health and any side effects they might experience.
The trial aims to provide valuable information on how to best manage patients with these heart conditions, ensuring they receive the safest and most effective treatment. The results will help doctors make informed decisions about using Lixiana in patients with atrial fibrillation and heart syndromes, especially after they have had a PCI procedure.



Belgium
Denmark
Italy
The Netherlands